Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
Lancet
; 390(10102): 1585-1594, 2017 Sep 30.
Article
en En
| MEDLINE
| ID: mdl-28755782
Texto completo:
1
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Idioma:
En
Revista:
Lancet
Año:
2017
Tipo del documento:
Article